Skip to content
Screener

Tandem Diabetes Care TNDM Q1 2025 earnings

Reported April 30, 2025 · After market close

Revenue$234.4MBeat by $14.2M
EPS-$0.67Miss by $0.07
Revenue estimate$220.2M
EPS estimate-$0.60

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$266.1M
EPS estimate-$0.26

Financials

Q1 2025

Income statement

See full
Revenue$234.4M+22.3%
Gross profit$118.4M+25.1%
Operating income-$120.9M-190%
Net income-$130.6M-206%
EPS (diluted)-$1.97-203%

Balance sheet

See full
Cash & equivalents$53.6M-9.2%
Total debt$493.2M+279%
Total equity$155.3M-36.1%
Total assets$922.1M-2.0%

Cash flow

See full
Operating cash flow-$18.3M-129%
CapEx$3.0M-33.5%
Free cash flow-$21.2M-70.6%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$1.27B-45.2%
Enterprise value$1.71B-28.5%
P/S1.3×-1.7×

Profitability

See full
Gross margin52.2%+2.9pp
Operating margin-18.1%-0.9pp
Net margin-18.7%+0.3pp
FCF margin-0.4%-0.2pp

Returns & leverage

See full
Return on equity-92.3%+817pp
Debt / equity3.2×+2.6×
Current ratio2.3×-1.5×

Segments

By product

See full
Supplies and other$132.3M+25.4%
Pump$102.1M+17.0%

FAQ

When did Tandem Diabetes Care report Q1 2025 earnings?
Tandem Diabetes Care (TNDM) reported Q1 2025 earnings on April 30, 2025 after market close.
What were Tandem Diabetes Care's Q1 2025 revenue and EPS?
Tandem Diabetes Care reported revenue of $234.4M and eps of $-0.67 for Q1 2025.
Did Tandem Diabetes Care beat estimates in Q1 2025?
Revenue beat the consensus estimate of $220.2M by $14.2M. EPS missed the consensus estimate of $-0.60 by $0.07.
How did Tandem Diabetes Care's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 22.3% from $191.7M a year earlier and eps declined 6.3% from $-0.63.
Where can I find Tandem Diabetes Care's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001438133-25-000068) and the 10-Q periodic report (0001438133-25-000069) directly on SEC EDGAR. The filing index links above go to sec.gov.